Reports revealed that treatment of 1α, 25(OH)2D3 downregulates BCL2 expression in MCF-7 breast tumor and HL-60 leukemia cells and increase protein expression of BAX and BAK in prostate cancer, colorectal adenoma, and carcinoma cells. This evidence concerns the gene BAK1 and colorectal adenoma.